Semaglutide vs Tirzepatide vs Retatrutide
The cleanest way to tell these three apart: single vs dual vs triple agonist. Here is the dose-free, physician-reviewed comparison — receptor targets, FDA status, and indications.
Medically reviewed by Charles Kamen, MD, board-certified neurologist ·
The defining difference between semaglutide, tirzepatide, and retatrutide is how many metabolic pathways each one activates: semaglutide is a single GLP-1 agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide is a triple GIP/GLP-1/glucagon agonist. Semaglutide and tirzepatide are FDA-approved and prescribable today; retatrutide is investigational and not FDA-approved as of June 2026.
This page is a dose-free reference — it does not state strengths or titration, because those are clinical decisions made by a physician, not facts to publish. For a deeper look at any single pairing, see our semaglutide vs tirzepatide and tirzepatide vs retatrutide comparisons.
Note: This table compares only receptor targets, regulatory status, indications, and form — never doses or titration, which are clinical decisions. Tirzepatide (as Zepbound) is the only one of the three FDA-approved for obstructive sleep apnea — the first medication the FDA ever approved for OSA (December 2024). Reviewed by Charles Kamen, MD against the FDA Drugs@FDA database; retatrutide’s investigational status is verified at the time of care.
Single vs dual vs triple agonist — what does it mean?
“Single, dual, and triple agonist” simply counts how many hormone receptors a medication activates. GLP-1 and GIP are incretin hormones that influence appetite, insulin release, and how the body handles food; glucagon affects energy expenditure and how the liver handles fat and glucose. Activating more pathways is the rationale behind newer agents — but more pathways is not automatically “better” for a given person, and the question that matters clinically is what is appropriate and safe for you. For where retatrutide stands and the FDA-approved alternatives available now, see our retatrutide guide.
Semaglutide vs Tirzepatide vs Retatrutide — FAQ
What is the difference between semaglutide, tirzepatide, and retatrutide?
The defining difference is how many metabolic pathways each one activates: semaglutide is a single GLP-1 receptor agonist, tirzepatide is a dual agonist targeting GIP and GLP-1, and retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon. Semaglutide and tirzepatide are FDA-approved and prescribable today; retatrutide is investigational and not FDA-approved as of June 2026.
Which of these are FDA-approved?
Semaglutide and tirzepatide are FDA-approved; retatrutide is not. Semaglutide is approved for type 2 diabetes and chronic weight management; tirzepatide is approved for type 2 diabetes, chronic weight management, and — as Zepbound in 2024 — obstructive sleep apnea, the first medication ever FDA-approved for OSA. Retatrutide remains in clinical trials and is not FDA-approved as of June 2026.
Is retatrutide better than tirzepatide or semaglutide?
No comparison table can answer "better" for a specific person, and any source claiming a definitive winner for everyone is overstating what is known. Retatrutide adds a third pathway (glucagon) and is being studied closely, but it is investigational and not available as a standard prescription. Tirzepatide and semaglutide have large completed clinical-trial programs and FDA approval behind them. The right choice depends on an individual's health profile and is a physician decision.
Can I get retatrutide by prescription?
No — because retatrutide is investigational and not FDA-approved, no clinic can dispense it as a standard prescription in Las Vegas or anywhere else. Products sold online as "research use only" retatrutide are not manufactured or tested for human use, and we strongly recommend against them. FDA-approved options such as semaglutide and tirzepatide are available after a medical evaluation.
What do GLP-1, GIP, and glucagon actually do?
GLP-1 and GIP are incretin hormones that influence appetite, insulin release, and how the body handles food; glucagon affects energy expenditure and how the liver handles fat and glucose. Activating more of these pathways at once is the rationale behind dual and triple agonists — though more pathways does not automatically mean better for a given individual. This is general mechanism information and does not predict how any individual will respond.
How does a physician choose between these medications?
A physician chooses based on your diagnosis, health history, contraindications, prior response, insurance and availability, and treatment goals — not on which drug targets the most receptors. Among FDA-approved options, the evaluation weighs benefits and risks for your specific situation, with lab work and follow-up monitoring. Retatrutide is discussed as an investigational option only, with an honest account of its current status.
Related reading: All GLP-1 medications compared · Medical weight loss in Las Vegas · Which peptides are FDA-approved?
Physician-Led in Las Vegas
Which one is right for you? Ask a physician.
A table compares molecules; a physician evaluates you. Start with an $88 medical evaluation, and Dr. Kamen will review the FDA-approved options against your health profile — and give you an honest account of where investigational agents like retatrutide stand.
Ready to start your longevity care?
Book your $88 evaluation with Dr. Kamen today, online, by phone, or by text.
Prefer to talk? Call (702) 808-2650 or text us to book.
Also serving Henderson — or explore semaglutide weight loss in Las Vegas.